[CAS NO. 1936529-65-5]  YKL-05-099

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1936529-65-5]

Catalog
HY-101147
Brand
MCE
CAS
1936529-65-5

DESCRIPTION [1936529-65-5]

Overview

MDLMFCD31382123
Molecular Weight600.11
Molecular FormulaC32H34ClN7O3
SMILESO=C1N(C2=NC=C(OC)C=C2)C3=NC(NC4=CC=C(C5CCN(C)CC5)C=C4OC)=NC=C3CN1C6=C(C)C=CC=C6Cl

For research use only. We do not sell to patients.


Summary

YKL-05-099 is a salt-inducible kinase ( SIK ) inhibitor. YKL-05-099 binds to SIK1 and SIK3 with IC 50 s of ~10 and ~30 nM, respectively. YKL-05-099 has slightly less potent SIK2-inhibitory (IC 50 =40 nM) [1] .


IC50 & Target

IC50: 10 nM (SIK1), 30 nM (SIK3), 40 nM (SIK2) [1]


In Vitro

YKL-05-099 has slightly less potent SIK2-inhibitory (IC 50 =40 nM) and IL-10-enhancing activities (EC 50 =460 nM). YKL-05-099 binds to SIK1 and SIK3 with IC 50 s of 10 and 30 nM, respectively, in a competitive binding assay. Preincubating bone marrow-derived macrophages with YKL-05-099 reduces LPS stimulated phosphorylation of HDAC5 at the SIK-specific phosphorylation site Ser259. YKL-05-099 suppresses production of the inflammatory cytokines TNFα, IL-6 and IL-12p40, and only modestly enhances IL-1β release in BMDCs stimulated with the yeast cell wall extract Zymosan A [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

YKL-05-099 is non-toxic at concentrations less than 10 μM and stable in mouse liver microsomes for more than 2 hours. YKL-05-099 is highly soluble (PBS solubility=428 μM) and present in an unbound state at appreciable levels in mouse plasma. YKL-05-099 dose dependently decreases phosphorylation of HDAC5 at the SIK-regulated site Ser259; reduced phosphorylation is observed at the lowest dose (5 mg/Kg) and is below the limit of detection by immunoblotting beginning at the 20 mg/Kg dose. YKL-05-099 dose-dependently reduces abundance of TNFα in serum beginning at 5 mg/Kg, and increases IL-10 levels at the 20 mg/Kg dose by more than 2-fold [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 75 mg/mL ( 124.98 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6664 mL 8.3318 mL 16.6636 mL
5 mM 0.3333 mL 1.6664 mL 3.3327 mL
10 mM 0.1666 mL 0.8332 mL 1.6664 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (4.17 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.17 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.17 mM); Clear solution

* All of the co-solvents are available by MCE.